4DMT Appoints Kristian Humer as Chief Financial Officer [Yahoo! Finance]
Foghorn Therapeutics Inc. (FHTX)
Company Research
Source: Yahoo! Finance
or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company's financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives. Mr. Humer is an accomplished finance executive and biotechnology leader with more than two decades of experience spanning corporate finance, strategic operations and healthcare investment banking. During his tenure at Citi, he held progressively senior roles, culminating as Managing Director in Citi's Healthcare Investment Banking Group, where he worked from 2010 to 2021. He advised clients across the global biopharma sector on strategic initiatives including equity and equity-linked financings, mergers and
Show less
Read more
Impact Snapshot
Event Time:
FHTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHTX alerts
High impacting Foghorn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
FHTX
News
- Foghorn Therapeutics (NASDAQ:FHTX) was given a new $12.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=FHTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- 4D Molecular Therapeutics taps Kristian Humer as CFO [Seeking Alpha]Seeking Alpha
- Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $12.00 price target on the stock.MarketBeat
FHTX
Earnings
- 11/5/25 - Beat
FHTX
Sec Filings
- 12/4/25 - Form 8-K
- 11/17/25 - Form 4
- 11/7/25 - Form 8-K
- FHTX's page on the SEC website